
      



  
    


      
    Guidance
  

  
  
    Assessment and procurement of coronavirus (COVID-19) tests
  

  
  

  
    
  How the government assesses offers of COVID-19 tests from developers for procurement and use in the UK.

  



  
    
      
  
      From:
      
          Department of Health and Social Care

      
      Published
      3 June 2020
      Last updated
      
        1 December 2021
          — 
            See all updates
          
      
  

    
    
    
  










  
    
      

      
          
    Documents


      

    
        
  
      
  
  
    National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests
    
        HTML
    


  

  
      
  
  
    Products in the pipeline (TVG): validation concluded or paused
    
        HTML
    


  

  
      
  
  
    Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)
    
        HTML
    


  

  
      
  
  
    Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) 
    
        HTML
    


  

  
      
  
  
    Technical validation protocol for SARS-CoV-2 nucleic acid detection
    
        HTML
    


  

  
      
  
  
    National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests
    
        HTML
    


  

  
      
  
  
    COVID-19 test approval – step 2: process for desktop review
    
        HTML
    


  



  


        
          Details


          

    
            
This page contains guidance to help developers of COVID-19 tests understand how their tests are assessed for procurement and use in the UK.



        
      

      
    Published 3 June 2020
    Last updated 1 December 2021
      + show all updates
      
        
            
              1 December 2021
              Updated 'Validated technology' table in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to add another molecular device.
            
            
              11 October 2021
              Updated 'Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)' to add 6 more lateral flow devices that have passed 3a validation.
            
            
              4 October 2021
              Updated the appeals process within 'National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests'.
            
            
              30 September 2021
              Updated 'National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests' to include all new products in the pipeline as of 13 September 2021.
            
            
              21 September 2021
              Added new test: SARS CoV-2 + Influenza A/B (Roche Cobas Liat) to the 'Validated technology' table in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests'.
            
            
              8 September 2021
              Updated 'COVID-19 test approval – step 2: process for desktop review' to explain the use of the full dynamic range data for the regulation assessment and add an email address to request TVG data.
            
            
              20 August 2021
              Removed 'Coronavirus test device authorisations operating process for SARS-CoV-2 tests' as out of date. Up-to-date information is in the document 'COVID-19 test approval – step 2: process for desktop review'.
            
            
              17 August 2021
              Added updated guidance 'COVID-19 test approval – step 2: process for desktop review' to replace 'Coronavirus test device authorisations: desktop review (stage 2) operating process for SARS-CoV-2 tests'. The guidance has been updated to include information on the requirements for the comparator test, the performance thresholds for different technology types and an explanation of how the performance of a test will be assessed against the thresholds.
            
            
              9 August 2021
              Updated to add 2 further validated lateral flow devices to the table in 'Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)'.
            
            
              3 August 2021
              Temporarily removed 'Coronavirus test device authorisations: desktop review (stage 2) operating process for SARS-CoV-2 tests' while it is being updated.
            
            
              26 July 2021
              Updated the 'Validated technology' table in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to add 3 new tests: BD Veritor System and VMD Health (UK) and Alveo Technologies Inc.: be.well™ COVID-19 test. Added 'Assure Tech Ecotest COVID-19 Antigen Rapid Test Device' to Outcome of the evaluation of rapid diagnostic assays for specific sars cov-2 antigens lateral flow devices.
            
            
              19 July 2021
              Updated the number of lateral flow devices PHE Porton Down and University of Oxford SARS-CoV-2 lateral flow antigen test validation cell has evaluated in the 'Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)' attachment.
            
            
              7 July 2021
              Updated the number of lateral flow devices PHE Porton Down and University of Oxford SARS-CoV-2 lateral flow antigen test validation cell has evaluated in the  'Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)' attachment.
            
            
              2 July 2021
              Updated the 'Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)' document to add lateral flow devices that have passed 3a validation.
            
            
              17 June 2021
              Added attachments 'Coronavirus test device authorisations operating process for SARS-CoV-2 tests' and 'Private testing desktop review (stage 2): operating process for SARS-CoV-2 tests'.
            
            
              15 June 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to update the 'Validation stage' table.
            
            
              3 June 2021
              Updated the 'Validated technology' table in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to add 3 new tests: Certest Biotech Viasure qRT-PCR, Randox Rapid PCR and Thermo Fisher Taqpath PCR.
            
            
              26 May 2021
              Updated 'Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)' to add 5 more lateral flow devices that have passed 3a validation.
            
            
              4 May 2021
              Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to add detail on performance results in the 'Validated technology' section.
            
            
              21 April 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to update the 'Validation stage' table.
            
            
              19 April 2021
              Updated list of validated LFD tests ('Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)').
            
            
              7 April 2021
              Updated the attachment 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to update the products in the pipeline table.
            
            
              6 April 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to add new validated technology, 'DNANudge'.
            
            
              30 March 2021
              Updated the attachment 'National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests' to update the products in the pipeline table.
            
            
              17 March 2021
              Updated the National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests document to add information about antibody test manufacturers.
            
            
              15 March 2021
              Added new document: 'National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests'.
            
            
              12 March 2021
              Updated and removed a table from the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to create the new document 'Products in the pipeline (TVG): validation concluded or paused'.
            
            
              5 March 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to update the 'Validation stage' table.
            
            
              3 February 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to add 2 new validated technologies, 'LumiraDx: POC rapid COVID-19 Ag test' and 'Primer Design Ltd: PROmate direct: qRT-PCR'.
            
            
              1 February 2021
              Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to reflect the number of technologies currently in the TVG pipeline.
            
            
              11 January 2021
              Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to clarify the procurement process and to reflect the number of technologies currently in the TVG pipeline.
            
            
              8 January 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to add a new validated technology, Abbott.
            
            
              8 January 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to delete a validated technology (Latus) and add a new validated technology (Nonacus).
            
            
              7 January 2021
              Updated the 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' document to update the 'Products in the pipeline' table and add a new validated technology, Latus.
            
            
              23 December 2020
              Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests': added guidance for antibody test manufacturers about registering interest; added that an alternative technical validation route will be required for any non-machine based LFT and home testing kits; and removed Tenders Electronic Daily as a source of further procurement opportunities.
            
            
              23 December 2020
              Added Oxford Nanopore: LamPORE: RNA RT-qPCR to validated technology table in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests'.
            
            
              22 December 2020
              Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to reflect the number of technologies currently in the TVG pipeline.
            
            
              17 December 2020
              Updated 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' to add a new validated technology (QuantuMDx), edited links under 'Publication of results' and amended title of 'First wave of non-machine based lateral flow technology (LFT) assessment' to 'First wave of lateral flow test and non-machine based LFT assessment'.
            
            
              7 December 2020
              In the attachment ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19), updated information about technologies in the pipeline, added new information about validations concluded or paused and added new information and reports on validated technology.
            
            
              23 October 2020
              In 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests', updated information about technologies in the pipeline.
            
            
              5 October 2020
              Small amendments made to first 2 paragraphs in 'National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests' for clarity.
            
            
              23 September 2020
              Updated to reflect the new process for validating new COVID-19 viral detection tests. Previously these were assessed by a group called the Viral Detection Test Advisory Group (VTAG) but this process has changed.
            
            
              11 August 2020
              This guidance now only applies to viral detection testing. The guidance has been updated to reflect that the New Tests Advisory Group is no longer accepting new serology or antibody tests.
            
            
              3 June 2020
              First published.
            
        
      



      
    
  
  

  


    
  

      
        Related content
      




      


  


        Coronavirus COVID-19 serology and viral detection tests: technical validation reports
        Lateral flow validation prioritisation criteria for rapid diagnostic assays for specific SARS-CoV-2 antigens
        COVID-19 test approval: how to apply
        Technologies Validation Group: using tests to detect COVID-19
        Medical devices: UK approved bodies

  


  



    


  Brexit
  
    Check what you need to do









  
    
        
  
    
  





      

    Explore the topic

  


        Testing for coronavirus (COVID-19)

  


  

  


    
  


    